COLORADO: The establishment of retail cannabis sales for adults is not associated with either increased marijuana access or use by young people, according to data published online in the journal Prevention Science.
A team of investigators with the University of Colorado, School of Public Health assessed marijuana use trends among a representative sample of Colorado high-school students for the years just prior to the implementation of retail sales and again 18-months later.
Authors reported: “There was an absence of significant effects for change in lifetime or past 30-day marijuana use. Among those reporting past 30-day use, frequent use and use on school property declined. There was a significant decline in the perceived harm associated with marijuana use, but we did not find a significant effect for perceived wrongfulness, perceived ease of access, or perceived parental disapproval.”
They concluded, “We did not find a significant effect associated with the introduction of legal sales of recreational marijuana to adults in Colorado on adolescent (illegal) use.”
The data is consistent with prior studies finding that neither the enactment of medical cannabis legalization nor the enactment of adult use regulation is independently associated with increased marijuana use by young people. Separate survey data released by the Department of Public Health and Environment last month reported that rates of marijuana use by Colorado teens have remained virtually unchanged following legalization, and are consistent with the national average.
For more information, contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org. Full text of the study, “Adolescent marijuana use, marijuana-related perceptions, and use of other substances before and after initiation of retail marijuana sales in Colorado (2013-2015),” appears in Prevention Science.
FLORIDA: Alternative Medical Enterprises, a fully integrated company that brings pharmaceutical industry precision to the development, production and dispensing of medical cannabis, announced it has closed a private placement financing of $35.4 million with an affiliate of MainLine Investment Partners and other investors.
“This Financing will help us to conduct a robust launch in the massive medical marijuana marketplace of Florida and build out our 25 authorized dispensaries,” said Matthew Duffy, AltMed President and COO. “It will also enable us to accelerate the expansion of our cultivation capabilities and increase our footprint in Arizona. We anticipate significant growth over the next few years as we expand our licensed facilities to meet the needs of medical cannabis patients in Florida and Arizona.”
Additionally, the investment will provide capital to grow AltMed’s award winning MÜV brand of premium cannabis products nationally & internationally. Funding will also clear the balance sheet of debt and allow AltMed’s industry leading R&D to continue to prosper.